My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Novartis AG Common Stock (NY:NVS)

137.87 -0.85 (-0.61%)

Official Closing Price Updated: 7:00 PM EST, Dec 31, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

53 54 Next >

This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks ↗

December 10, 2023

Regulators are already on the case, and their findings will have financial impacts.

Via The Motley Fool

A Comprehensive Study Exploring Breast Cancer Treatment Market : Key Players Gilead Sciences, Astellas, Celgene

December 07, 2023

Get an extensive Breast Cancer Treatment Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry.

Via SBWire

Zoetis Stock A Good Companion For Your Portfolio? Shares Rising ↗

December 07, 2023

Reflecting strong fundamentals, Zoetis stock boasts a best-possible A SMR Rating (sales+profit margins+return on equity) on an A-to-E scale.

Via Investor's Business Daily

Novartis' Rare Blood Disorder Therapy Scores FDA Approval ↗

December 06, 2023

The FDA approved Novartis AG's (NYSE

Via Benzinga

(NVS) - Analyzing Novartis's Short Interest ↗

December 01, 2023

Via Benzinga

How Is The Market Feeling About Novartis? ↗

November 10, 2023

Via Benzinga

Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week ↗

October 30, 2023

S&P 500 earnings is expected to grow in Q3, reversing a four-quarter slide, as the reporting season enters its third week.

Via Benzinga

Topics Economy Stocks

Allergy Treatment Market Know Faster Growing Segments Now: Akorn, Pfizer, Novartis, Mylan N.V ↗

November 30, 2023

Global Allergy Treatment Market Breakdown by Application (Hospitals, Specialty Clinics, Homecare, Others) by Type (Eye Allergy, Food Allergy, Skin Allergy, Asthma, Rhinitis, Others) by Treatment...

Via SBWire

Anti-Inflammatory Drugs Market Boosting the Growth Worldwide 2030

November 29, 2023

Get Anti-inflammatory Drugs Market analysis, key vendors & competitive scenario of the market prepared using market research tools such as Porter’s five forces and SWOT analysis.

Via SBWire

Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies ↗

November 29, 2023

Tuesday, the FDA said it received reports of patients developing T-cell malig

Via Benzinga

3 Healthcare Stocks to Pick Up Before the Year-End Rally ↗

November 28, 2023

Explore the potential of healthcare stocks as the U.S. charges ahead with $4.3 trillion in healthcare spending

Via InvestorPlace

Novartis Outlines Pure-Play Strategy Progress After Generics Business Spin-Off ↗

November 28, 2023

Novartis AG (NYSE: NVS) has outlined the progress made in delivering its pure-play strategy, focused on four core therapeutic areas (Cardiovascular-Renal-Metabolic, Immunology, Neuroscience, Oncology),...

Via Benzinga

Gene Therapy Market Research: Exploring Market Size, Business Growth, Career Prospects, Industry Trends, and Projections for 2028 ↗

November 27, 2023

Northbrook, IL 60062 -- (SBWIRE) -- 11/27/2023 -- In May 2022, Novartis AG (Switzerland) received US FDA approval for KYMRIAH (Tisagenlecleucel) for a third indication, including relapsed or refractory...

Via SBWire

Olema Stock Has Soared 551% This Year. Its CEO Thinks It's Still Undervalued. ↗

November 22, 2023

The company is working on treatments for breast cancer in a market worth $15 billion, according to the CEO.

Via Investor's Business Daily

2 overlooked stocks that crushed earnings but traded lower

November 20, 2023

As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results

Via MarketBeat

Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal ↗

November 18, 2023

Legend Biotech partnered its DLL3 CAR-T candidates to Novartis in a $1.2 billion agreement, with $100 million offered upfront. Novartis will own worldwide rights to develop, manufacture, and...

Via Talk Markets

Diversifying Your Portfolio With Plant-Based Options ↗

November 16, 2023

Investors see profit potential in the plant-based market due to rising consumer demand, ESG focus, and the growth of vegan products in various industries, including pharmaceuticals. However, market...

Via Talk Markets

Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On ↗

November 16, 2023

Unsurprisingly, Johnson & Johnson's top investments are all in the healthcare sector.

Via The Motley Fool

Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030

November 14, 2023

EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NYSE:BMY),(NYSE:NVS),(NYSE:MRK),(OTCQX:RHHBY) EQNX::TICKER_END

Via FinancialNewsMedia

Verve Loses A Third Of Its Value As Safety Concerns Plague Its Gene-Editing Drug ↗

November 13, 2023

Patients had big decreases in LDL cholesterol. But there were some side effects.

Via Investor's Business Daily

3 Spectacular High-Yield Dividend Stocks to Buy in November ↗

November 05, 2023

Income investors should find plenty to like with these stocks.

Via The Motley Fool

Get Ready for Next Generation of Diabetes, Weight-Management Drugs

November 01, 2023

Via Investor Brand Network

Get Ready for Next Generation of Diabetes, Weight-Management Drugs

November 01, 2023

EQNX::TICKER_START (NASDAQ:LEXX),(NYSE:JNJ),(NYSE:SNY),(NASDAQ:AMGN),(NYSE:NVS) EQNX::TICKER_END

Via FinancialNewsMedia

Novartis' Rare Kidney Disease Candidate Aces Late-Stage Study ↗

October 30, 2023

Novartis AG (NYSE: NVS) released topline results from the interim analysis of the ongoing pivotal Phase 3 ALIGN study of atrasentan in patients with IgA nephropathy (IgAN). IgAN is a major cause of...

Via Benzinga

Are Your Eyes At Grave Risk? FDA Issues Dangerous Warning Over Popular Drops From CVS, Target, Cardinal Health And More ↗

October 28, 2023

The U.S.

Via Benzinga

3 No-Brainer Stocks to Buy for Under $100 Right Now ↗

October 28, 2023

A couple of these stocks might not be available for under $100 for too much longer.

Via The Motley Fool

2 Green Flags and 1 Red Flag for Novartis Stock ↗

October 27, 2023

The Swiss pharmaceutical company just posted strong Q3 numbers and is going through some big changes.

Via The Motley Fool

7 Undervalued Stocks to Buy Before Everyone Else ↗

October 26, 2023

Buy these undervalued stocks while they trade at a significant discount compared to their intrinsic valuations.

Via InvestorPlace

Sanofi Stock Relative Strength Rating Jumps To 84: One To Watch ↗

October 24, 2023

Additionally, Sanofi stock has a decent 83 Composite Rating out of 99, and an 80 Earnings Per Share Rating.

Via Investor's Business Daily

Novartis Ag (NVS) Q3 2023 Earnings Call Transcript ↗

October 24, 2023

NVS earnings call for the period ending September 30, 2023.

Via The Motley Fool

Topics Earnings

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

53 54 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.